RU2733401C2 - Комбинации противораковых лекарств - Google Patents

Комбинации противораковых лекарств Download PDF

Info

Publication number
RU2733401C2
RU2733401C2 RU2016143153A RU2016143153A RU2733401C2 RU 2733401 C2 RU2733401 C2 RU 2733401C2 RU 2016143153 A RU2016143153 A RU 2016143153A RU 2016143153 A RU2016143153 A RU 2016143153A RU 2733401 C2 RU2733401 C2 RU 2733401C2
Authority
RU
Russia
Prior art keywords
acceptable salts
cancer
physiologically acceptable
compound
compounds
Prior art date
Application number
RU2016143153A
Other languages
English (en)
Russian (ru)
Other versions
RU2016143153A3 (enExample
RU2016143153A (ru
Inventor
Бейард Р. Хак
Эрик УИЛКЕР
Андреас МАЧЛ
Ремигиуш КАЛЕТА
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of RU2016143153A publication Critical patent/RU2016143153A/ru
Publication of RU2016143153A3 publication Critical patent/RU2016143153A3/ru
Application granted granted Critical
Publication of RU2733401C2 publication Critical patent/RU2733401C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016143153A 2014-04-03 2015-03-09 Комбинации противораковых лекарств RU2733401C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461974765P 2014-04-03 2014-04-03
US61/974,765 2014-04-03
PCT/EP2015/000525 WO2015149909A1 (en) 2014-04-03 2015-03-09 Combinations of cancer therapeutics

Publications (3)

Publication Number Publication Date
RU2016143153A RU2016143153A (ru) 2018-05-04
RU2016143153A3 RU2016143153A3 (enExample) 2018-10-17
RU2733401C2 true RU2733401C2 (ru) 2020-10-01

Family

ID=52692591

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016143153A RU2733401C2 (ru) 2014-04-03 2015-03-09 Комбинации противораковых лекарств

Country Status (15)

Country Link
US (1) US9980966B2 (enExample)
EP (1) EP3125935B1 (enExample)
JP (1) JP6629753B2 (enExample)
KR (1) KR102410696B1 (enExample)
CN (1) CN106456752B (enExample)
AR (1) AR099931A1 (enExample)
AU (1) AU2015240094B2 (enExample)
CA (1) CA2944573C (enExample)
ES (1) ES2768900T3 (enExample)
IL (1) IL248126A0 (enExample)
MX (1) MX370540B (enExample)
NZ (1) NZ725361A (enExample)
RU (1) RU2733401C2 (enExample)
SG (1) SG11201608189WA (enExample)
WO (1) WO2015149909A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302951A (en) * 2020-11-16 2023-07-01 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
AU2025220299A1 (en) * 2024-02-05 2026-07-16 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429006C2 (ru) * 2005-02-18 2011-09-20 Дженентек, Инк. Комбинация apo2l/trail и ингибитора egfr для лечения рака, способ in vitro усиления апоптоза и применение комбинации для получения лекарственного средства для лечения рака
WO2012069146A1 (en) * 2010-11-24 2012-05-31 Merck Patent Gmbh Quinazoline carboxamide azetidines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7547794B2 (en) 2003-04-03 2009-06-16 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7189729B2 (en) 2003-09-30 2007-03-13 Irm Llc Methods and compositions as protein kinase inhibitors
US7816353B2 (en) 2003-10-24 2010-10-19 Exelixis, Inc. P70S6 kinase modulators and method of use
RU2006121646A (ru) 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
BRPI0417498A (pt) 2003-12-09 2007-05-29 Us Gov Health & Human Serv método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascular
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
AU2005322085B2 (en) 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
CN101300029A (zh) * 2005-11-04 2008-11-05 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
KR101699991B1 (ko) 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
MX370448B (es) 2013-03-11 2019-12-13 Merck Patent Gmbh Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429006C2 (ru) * 2005-02-18 2011-09-20 Дженентек, Инк. Комбинация apo2l/trail и ингибитора egfr для лечения рака, способ in vitro усиления апоптоза и применение комбинации для получения лекарственного средства для лечения рака
WO2012069146A1 (en) * 2010-11-24 2012-05-31 Merck Patent Gmbh Quinazoline carboxamide azetidines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GARCIA-GARCIA C et al. Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy. CLINICAL CANCER RESEARCH, 2012, vol. 18, no. 9, p. 2603 - 2612. *
VAZQUEZ-MARTIN A et al. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) in human breast carcinoma cells. ANNALS OF ONCOLOGY, 2008, vol. 19, no. 6, p.1097 - 1109. *

Also Published As

Publication number Publication date
JP6629753B2 (ja) 2020-01-15
RU2016143153A3 (enExample) 2018-10-17
EP3125935B1 (en) 2019-10-23
WO2015149909A1 (en) 2015-10-08
NZ725361A (en) 2022-09-30
US9980966B2 (en) 2018-05-29
CA2944573A1 (en) 2015-10-08
MX2016012825A (es) 2017-01-05
AU2015240094B2 (en) 2020-07-30
SG11201608189WA (en) 2016-10-28
ES2768900T3 (es) 2020-06-24
AU2015240094A1 (en) 2016-11-17
AR099931A1 (es) 2016-08-31
KR102410696B1 (ko) 2022-06-17
CA2944573C (en) 2022-10-25
JP2017509683A (ja) 2017-04-06
MX370540B (es) 2019-12-17
BR112016020135A8 (pt) 2021-07-06
EP3125935A1 (en) 2017-02-08
US20170100402A1 (en) 2017-04-13
CN106456752A (zh) 2017-02-22
KR20160133005A (ko) 2016-11-21
IL248126A0 (en) 2016-11-30
BR112016020135A2 (pt) 2017-08-15
CN106456752B (zh) 2020-11-20
RU2016143153A (ru) 2018-05-04

Similar Documents

Publication Publication Date Title
CN107864625A (zh) 含有取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉的组合产品
AU2013234767B2 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
US20180110831A1 (en) Cd 47 containing porous nanoparticle supported lipid bilayers (protocells) field of the invention
US9980966B2 (en) Combinations of cancer therapeutics
CA3191515A1 (en) Stat-activated macrophages, compositions, and uses thereof
BR112016020135B1 (pt) Mistura de compostos, seus usos, composição farmacêutica, e conjunto (kit)
US20200114001A1 (en) Combinations of copanlisib with anti-pd-1 antibody
RU2854156C1 (ru) Комбинация ингибитора метионин аминопептидазы-2 и ингибитора рфрэс/фрэс
US20240024324A1 (en) Kinase inhibitor combinations for cancer treatment
AU2021303438B2 (en) Combination of a methionine aminopeptidase 2 inhibitor and VEGFR/VEGF inhibitor
US20240382495A1 (en) Combinations of copanlisib with anti-pd-1 antibody
CN116490187A (zh) 用于癌症治疗的激酶抑制剂组合